🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This is a really nice introduction to FOXL2!

HER2 low strikes again..do GEJ adenocarcinomas have it any better? This study doesn’t seem to think so!

Sage advice ... especially for us old-timers who begin with..."in our days" or "in the old days"...#tatawisdom

#Healthdata & #AI Annual Symposium at CMC Vellore (Official)

The 3rd Annual Cytokine Storm Symposium is coming soon! Join global experts for groundbreaking insights! Inviting complex cases for submission! Select cases feature in Prize Case Discussion with top experts Don’t miss this unique opportunity to learn engage & compete!Reg 🔗👇🏻

Serrated hyperplastic polyps are some of the commonest colonic polyps. But what features separate them from sessile serrated lesion/adenoma? - No Dysplasia - Serrations limited to the top - Base of crypts are free - No branching or horizontally spreading crypts #GIpath

Title: Reimagining WHO Tumor Classifications: A Global Call for Equity This piece is a brief summary of a thread that has evolved over the past 24 hours. It is by no means complete, but offers a snapshot for those who may not have been following the full conversation. In recent

The Sysmex Analyser is really going Bananas this morning 👇👇 Do you Share its sense of Excitement 😀 #medtwitter #meded #hematology #blooducation #Medicine HaemBytes

Inotuzumab ozogamicin (INO) being an anti CD22 therapy, Which of these 👇🏻refractory/Relapsed B-ALL patients are ideal for INO therapy. Red - Blast. Blue - Normal B lymphocytes. Green - Normal T lymphocytes.

Happy to share our paper on the “Efficiency of inotuzumab ozogamicin (InO) in relapsed/refractory B-Acute lymphoblastic leukemia in relation to CD22 expression”. In this pilot study we also studied the post-Ino CD22 modulation in residual leukemic cells. thieme-connect.com/products/ejour…

We found that InO was effective in R/R B-ALL, including in cases with weak CD22, and serve as bridging to HSCT Arun Kumar Arunachalam Kunal Sehgal Prashant Tembhare Ameet Kini, MD, PhD Sreejesh Sreedharanunni PHO INDIA Phaneendra Datari Gaurav Chatterjee Tribute to Hagop Kantarjian,MD for his extensive work on InO 🫡

Amazing!!

Lymph node core biopsy from adult with previous classical Hodgkin's lymphoma. More pictures in next tweet

Intraoperative flow proves to be much sensitive,objective&better technique in detecting FCC in peritoneal lavage fluid, helping in deciding on judicious radical cytoreductive surgery 4/4 Prashant Tembhare Kunal Sehgal ananthvikas Arun Kumar Arunachalam ICCS_Education THE CYTOMETRY SOCIETY

This is an eye opener!

Dear Shri Vishwajit Rane ji, Thank you for coming out with clarification. However it is riddled with holes. Let me point a few. 1. Commitment to basic medical care is good. GMC in fact provides high tech care. You have Govt centers which provide basic care. +

Join us for an Exciting meeting on "Consensus Recommendations and Workshops: Technical & Analytic Aspects of flow Cytometric B-ALL MRD" - An initiative by THE CYTOMETRY SOCIETY ICCS_Education

Do you work with B-ALL MRD #flowcytometry? Then you don’t want to miss this! The 1st ever consensus recommendations from #India based on an extensive survey with over 150 participants and experts. Interesting workshops as well! Book your spot now! THE CYTOMETRY SOCIETY Prashant Tembhare

If you are a true flow cytometrist or have passion to learn flow Cytometry, an event u cannot miss….